These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17627420)

  • 1. Tumor dosimetry on SPECT (186)Re-HEDP scans: variations in the results from the reconstruction methods used.
    Divoli A; Bloch G; Chittenden S; Malaroda A; O'Sullivan JM; Dearnaley DP; Flux GD
    Cancer Biother Radiopharm; 2007 Feb; 22(1):121-4. PubMed ID: 17627420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
    Denis-Bacelar AM; Chittenden SJ; McCready VR; Divoli A; Dearnaley DP; O'Sullivan JM; Johnson B; Flux GD
    Br J Radiol; 2018 Apr; 91(1084):20170795. PubMed ID: 29293372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
    de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
    J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trials of
    Denis-Bacelar AM; Chittenden SJ; Dearnaley DP; Divoli A; O'Sullivan JM; McCready VR; Johnson B; Du Y; Flux GD
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):620-629. PubMed ID: 27770145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
    Lam MG; Bosma TB; van Rijk PP; Zonnenberg BA
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1425-33. PubMed ID: 19319526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate.
    Israel O; Keidar Z; Rubinov R; Iosilevski G; Frenkel A; Kuten A; Betman L; Kolodny GM; Yarnitsky D; Front D
    J Clin Oncol; 2000 Jul; 18(14):2747-54. PubMed ID: 10894875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
    Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A
    Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases.
    Palmedo H; Guhlke S; Bender H; Sartor J; Schoeneich G; Risse J; Grünwald F; Knapp FF; Biersack HJ
    Eur J Nucl Med; 2000 Feb; 27(2):123-30. PubMed ID: 10755716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma.
    Syed R; Bomanji J; Nagabhushan N; Kayani I; Groves A; Waddington W; Cassoni A; Ell PJ
    J Nucl Med; 2006 Dec; 47(12):1927-35. PubMed ID: 17138735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
    Koutsikos J; Leondi A
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1392-3; author reply 1394-5. PubMed ID: 18438661
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
    Liepe K; Franke WG; Kropp J; Koch R; Runge R; Hliscs R
    Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
    Liepe K; Geidel HH; Bergmann R; Haase M; Runge R; Kotzerke J
    Nucl Med Commun; 2009 Sep; 30(9):693-9. PubMed ID: 19528873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
    Palmedo H; Bender H; Schomburg A; Grünwald F; Schöneich G; Zamorra P; Reichmann K; Dierke-Dzierzon C; Mallmann P; Biersack HJ
    Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.
    Limouris G; Shukla SK; Manetou A; Kouvaris I; Plataniotis G; Triantafyllou N; Rigas AV; Vlahos L
    Anticancer Res; 1997; 17(3B):1699-704. PubMed ID: 9179222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
    Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
    Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
    Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
    J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
    Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
    Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.